Bendamustine plus mitoxantrone for relapsed/refractory chronic lymphocytic leukaemia (CLL): results of a multicentre phase II study of the German CLL Study Group (GCLLSG)
Hubert Köppler, Harald Fuss, Hans J Hurtz, Owe Knigge, Christoph Losem, Daniel Reschke, Stephan Schmitz, Rudolf Weide, Johann Weiß, Michael Hallek, GCLLSG, Hubert Köppler, Harald Fuss, Hans J Hurtz, Owe Knigge, Christoph Losem, Daniel Reschke, Stephan Schmitz, Rudolf Weide, Johann Weiß, Michael Hallek, GCLLSG
Abstract
The efficacy of bendamustine (50 mg/m², days 1-3) plus mitoxantrone (10 mg/m², day 1), every 28 days for up to four courses, was evaluated in a Phase II multicentre trial enrolling 59 patients with relapsed or refractory B-cell chronic lymphocytic leukaemia (CLL). Major toxicities were grade 3/4 leucopenia, thrombocytopenia and infections in 42%, 12% and 12% of patients, respectively. Complete and partial response was achieved in 5/59 and 25/29 patients, respectively (overall response rate, 51%). Median time to progression was 22 months (range 1-49 + ) and median survival 27 months (range 0-49 + ). The combination of bendamustine and mitoxantrone is an active regime in relapsed or refractory CLL.
© 2012 Blackwell Publishing Ltd.
Source: PubMed